ArticleGut microbes2025
mbSparse: an autoencoder-based imputation method to address sparsity in microbiome data.
Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in microbiology: implications for metagenomics, diagnostics, and AMR surveillance.Biomedical engineering online · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The involvement of gut microbiota in host physiological activities is crucial, yet the high sparsity of microbiome data, marked by numerous zeros in count matrices, presents huge analytical challenges. To overcome this, we developed mbSparse, an imputation algorithm that leverages deep learning rather than traditional predefined count distributions. Utilizing a feature autoencoder for learning sample representations and a conditional variational autoencoder (CVAE) for data reconstruction, mbSparse effectively integrates these processes to enhance imputation. Our results demonstrate that mbSparse achieves exceptional accuracy, with mean squared error reductions of up to 4.1 compared to existing microbiome methods, even amid outlier samples and varying sequencing depths. In colorectal cancer analysis, mbSparse increases the detection of validated disease-associated taxa from 7 to 27, while predictive accuracy improves, as evidenced by area under the precision-recall area under the curve values rising from 0.85 to 0.93. Additionally, mbSparse addresses non-biological zeros by restoring over 88% of removed counts and achieving a Pearson correlation of 0.9354 at a 10% removal rate, preserving essential taxonomic relationships. Finally, our exploration of mbSparse variants reveals that the CVAE is critical for enhancing accuracy, providing valuable insights for further optimizing microbiome data imputation techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.